ERBB3 and neoplasm: The affibody demonstrated superior imaging properties for visualization of HER3‐expressing tumours in mice already at 3 h post‐injection compared to both the F(ab’)2‐fragment and the full‐length antibody at 48 and 96 h, respectively, corresponding to their most favourable imaging time‐points.